Skip to main content
TipRanks
Go Ultimate75% OFF

TuHURA Biosciences (HURA) AI Stock Analysis

1,030 Followers
HURA

TuHURA Biosciences

(NASDAQ:HURA)

Select Model
Rating:45Neutral
Price Target:$1.50â–²(10.29% Upside)
Action:reiterated
Date:11/13/26

The score is primarily held back by weak financial performance (no revenue, large recurring losses, and persistent negative free cash flow). Technicals also point to a bearish trend with the stock below key moving averages and negative MACD. Corporate events provide some liquidity and operational flexibility but also highlight continued dependence on financing and potential dilution, while valuation inputs are limited due to negative earnings and no dividend yield provided.

Positive Factors
Early clinical efficacyDurable responses in the initial IFx-2.0 study support the potential for meaningful clinical activity in a difficult cancer setting. If confirmed in broader studies, this signal could strengthen the program’s development prospects and differentiate TuHURA’s immunotherapy approach.
Negative Factors
No revenue and recurring lossesThe absence of revenue across annual and TTM periods shows that TuHURA has not yet established a commercial operating base. Recurring losses of roughly $29.9 million in TTM increase dependence on future financing and leave profitability contingent on successful clinical and commercial execution.

TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%HURA-28.04%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$89.43M
Dividend Yield
―
Average Volume (3M)
327.31K
Price to Earnings (P/E)
-2.7
Beta (1Y)
1.81
Revenue Growth
―
EPS Growth
24.26%
Country
US
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

TuHURA Biosciences Business Overview & Revenue Model

Company Description

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by whic...

TuHURA Biosciences Financial Statement Overview

Summary

Overall fundamentals are weak: the company reports no revenue and persistent sizable net losses (about ~$29.9M in TTM) alongside consistently negative free cash flow (about -$23.8M in TTM), indicating ongoing cash burn and reliance on external funding. The main offset is a relatively conservative balance sheet in recent periods with low leverage (debt-to-equity roughly ~0.01–0.02) and positive equity, which reduces near-term leverage risk.

Income Statement

12Very Negative

Balance Sheet

58Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue000000
Gross Profit-23.47K00-55.00K-60.00K-60.00K
EBITDA-27.97M-29.36M-17.43M-8.14M-14.28M-21.65M
Net Income-29.94M-30.06M-21.68M-8.32M-14.65M-22.66M
Balance Sheet
Total Assets36.24M27.35M19.97M4.36M15.20M6.40M
Cash, Cash Equivalents and Short-Term Investments1.89M3.62M12.66M3.67M14.25M5.55M
Total Debt9.56M700.02K202.54K2.34M138.22K644.07K
Total Liabilities17.29M6.42M5.37M5.92M2.89M7.15M
Stockholders Equity18.95M20.93M14.59M-1.56M12.30M-747.82K
Cash Flow
Free Cash Flow-23.82M-27.71M-14.79M-12.03M-7.54M-6.57M
Operating Cash Flow-23.61M-27.63M-14.73M-11.95M-7.51M-6.56M
Investing Cash Flow-213.67K-1.34M-6.05M-1.30M-36.28K-3,280
Financing Cash Flow23.02M19.93M29.77M2.66M16.25M7.04M

TuHURA Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price1.36

Price Trends

50DMA1.88Negative
100DMA2.04Negative
200DMA2.03Negative

Market Momentum

MACD-0.16Positive
RSI33.51Neutral
STOCH19.76Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.88, and below the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 33.51 is Neutral, neither overbought nor oversold. The STOCH value of 19.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HURA.

TuHURA Biosciences Risk Analysis

TuHURA Biosciences disclosed 62 risk factors in its most recent earnings report. TuHURA Biosciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our credit facility with Parkview Holdings One, LLC, which is secured by substantially all of our assets, together with the related royalty agreement with Parkview, could materially and adversely our financial condition and future operations and may cause substantial dilution to our stockholders.Q1, 2026
2.Disruptions and changes at the United States Food and Drug Administration (the "FDA") and other government agencies from funding cuts, personnel losses and changes, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.Q1, 2025
3.The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when approved.Q1, 2025

TuHURA Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HURA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AGENAGEN57Neutral$277.81M8.35-15.48%―25.38%―
INOINO55Neutral$320.29M-2.15-9999.00%―63.93%68.94%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CGTXCGTX45Neutral$57.12M-3.56-50.57%――62.99%
HURAHURA45Neutral$89.43M-2.72-146.80%――24.26%
BMEABMEA42Neutral$42.76M-1.86-131.27%――87.11%
SKYESKYE42Neutral$3.48M-0.10-503.95%――26.40%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%HURAAGENINOSKYEBMEACGTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HURA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HURATuhura Biosciences, Inc.1.36-0.38-21.84%
AGENAgenus Inc.6.141.9245.50%
INOInovio Pharmaceuticals1.71-0.05-2.84%
SKYESkye Bioscience, Inc.0.79-8.53-91.57%
BMEABiomea Fusion Inc0.59-0.39-40.00%
CGTXCognition Therapeutics, Inc.0.60-0.79-56.83%

TuHURA Biosciences Corporate Events

Private Placements and Financing

TuHURA Biosciences Borrows Additional Funds Under Credit Facility

Neutral
Nov 6, 2026

TuHURA Biosciences had entered a revolving credit facility with Parkview Holdings One LLC on April 21, 2026. On November 2, 2026, it borrowed an additional $1.5 million under the facility, which allows up to $50 million and matures April 21, 2031. Th...

Business Operations and StrategyPrivate Placements and Financing

TuHURA Biosciences Adds Borrowing Under Credit Facility

Neutral
Oct 16, 2026

On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC for a revolving credit facility of up to $50 million, maturing on April 21, 2031. This long-term financing arrangement provides the company with...

Business Operations and StrategyPrivate Placements and Financing

TuHURA Biosciences Draws Additional Funds From Credit Facility

Neutral
Sep 24, 2026

TuHURA Biosciences, Inc. entered into a revolving credit facility loan agreement with Parkview Holdings One LLC on April 21, 2026, providing up to $50 million in borrowing capacity and maturing on April 21, 2031. The arrangement underscores the compa...

Business Operations and StrategyPrivate Placements and Financing

TuHURA Biosciences Expands Use of Revolving Credit Facility

Neutral
Sep 17, 2026

TuHURA Biosciences, Inc. operates in the biotechnology and life sciences sector and is focused on developing medical and biopharmaceutical innovations. The company accesses external financing through structured credit facilities to support its operat...

Business Operations and StrategyRegulatory Filings and Compliance

TuHURA Biosciences Adopts 2026 Inducement Equity Plan

Positive
Sep 16, 2026

On September 10, 2026, TuHURA Biosciences’ board adopted a 2026 Inducement Equity Incentive Plan designed to grant equity awards to new employees as a material inducement to join the company or its subsidiaries. The plan reserves 5,000,000 shares of...

Business Operations and StrategyPrivate Placements and Financing

TuHURA Biosciences draws additional funds from credit facility

Positive
Sep 4, 2026

TuHURA Biosciences, Inc. previously entered into a revolving credit facility with Parkview Holdings One LLC on April 21, 2026, providing up to $50 million in loan availability and maturing on April 21, 2031. On September 2, 2026, the company drew an...

Business Operations and StrategyPrivate Placements and Financing

TuHURA Biosciences Expands Use of Revolving Credit Facility

Positive
Aug 21, 2026

On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC establishing a revolving credit facility of up to $50 million that matures on April 21, 2031. On August 20, 2026, the company drew an additional...

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings

TuHURA Biosciences Reports Results of 2026 Annual Meeting

Positive
Aug 19, 2026

On August 18, 2026, TuHURA Biosciences held its 2026 Annual Meeting, where a quorum of stockholders representing 43 million shares participated in key governance decisions. Shareholders elected six directors to serve until the 2027 Annual Meeting, ap...

Business Operations and StrategyPrivate Placements and Financing

TuHURA Biosciences Expands Use of Revolving Credit Facility

Positive
Aug 13, 2026

On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC for a revolving credit facility of up to $50 million, maturing on April 21, 2031. The agreement provides the company with flexible access to capi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026